TrimRX
US$ 22.35
retatrutide phase 2 nejm weight loss 48 weeks percent 2023 Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide Phase 2 NEJM Trial:
Description
Those who have lost massive amounts of weight need new wardrobes, and some opt for plastic surgery
In clinical trials, tirzepatide has shown substantial reductions in HbA1c and body weight, with effects varying by dose and patient population
Baseline characteristics were well balanced
Routine monitoring considerations: For most patients on GLP-1 therapy, routine magnesium level testing is not necessary
Subsequently, 50 L of peroxidase-coupled secondary antibody was distributed to each well and incubated for 1 h at 37 C
chemical degradation can also occur without any visible change
